Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis

Peritoneal Dialysis International

Volumn 28, Issue SUPP. 3, 2008, Pages

  Nakamoto, Hidetomo ^a   Imai, Hiroe ^a   Fukushima, Rie ^a   Ishida, Yuji ^a   Yamanouchi, Yasuhiro ^a   Suzuki, Hiromichi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin type 1 receptor blocker; ARB; Encapsulating peritoneal sclerosis; EPS; Peritoneal fibrosis; Renin angiotensin system

Indexed keywords

AMLODIPINE; DIALYSIS FLUID; GLUCOSE; OLMESARTAN;

ABDOMINAL DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOPSY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; ENCAPSULATING PERITONEAL SCLEROSIS; HISTOPATHOLOGY; HYPERTENSION; MICROSCOPY; NONHUMAN; PATHOGENESIS; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PERITONEAL FIBROSIS; PERITONEUM ADHESION; PH; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; WISTAR RAT;

AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; DIALYSIS SOLUTIONS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FIBROSIS; HYDROGEN-ION CONCENTRATION; HYPERTENSION, RENOVASCULAR; IMIDAZOLES; MALE; PERITONEAL DIALYSIS; PERITONEAL DISEASES; PERITONEUM; RATS; RATS, WISTAR; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 48749122043     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Shao JC, Yorioka N, Nishida Y, Yamakido M. Effect of pH and glucose on cultured human peritoneal mesothelial cells. Scand J Urol Nephrol 1999; 33:248-56.
2. Gandhi VC, Humayun HM, Ing TS, Daugirdas JT, Jablokow VR, Iwatsuki S, et al. Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch Intern Med 1980; 140:1201-3.
3. Nomoto Y, Kawaguchi Y, Kubo H, Hirano H, Sakai S, Kurokawa K. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis 1996; 28:420-7.
4. Slingeneyer A, Mion C, Mourad G, Canaud B, Faller B, Béraud JJ. Progressive sclerosing peritonitis: a late and severe complication of maintenance peritoneal dialysis. Trans Am Soc Artif Intern Organs 1983; 29:633-40.
5. Rottembourg J, Issad B, Langlois P, Tranbaloc R, Adamou A, DeGroc F, et al. Loss of ultrafiltration and sclerosing encapsutating peritonitis during CAPD evaluation of the potential risk factors. Adv CAPD 1985;1:109-17.
6. Slingeneyer A. Preliminary report on a cooperative international study on sclerosing encapsulating peritonitis. Contrib Nephrol 1987; 57:239-47.
7. Imai H, Nakamoto H, Ishida Y, Yamanouchi Y, Inoue T, Okada H, et al. Renin-angiotensin system plays an important role in the regulation of water transport in the peritoneum. Adv Perit Dial 2001; 17:20-4.
8. Ikoma M, Kawamura T, Kakinuma Y, Fogo A, Ichikawa I. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 1991; 40:195-202.
9. Jaimes EA, Galceran JM, Raij L. Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int 1998; 54:775-84.
10. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-62.
11. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Poht MA, Lewis JB, et al. on behalf of the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-60.
12. United States, National Research Council, Institute of Laboratory Animal Resources. Guide for the Care and Use of Laboratory Animals. Bethesda: United States Department of Health and Human Services, Public Health Service, National Institutes of Health; 1985.
13. Hao L, Kanno Y, Fukushima R, Watanabe Y, Ishida Y, Suzuki H. Effects of eplerenone on heart and kidney in two-kidney, one-clip rats. Am J Nephrol 2003; 24:54-60.
14. Wieczorowska K, Khanna R, Moore HL, Nolph KD, Twardowski ZJ. Rat model of peritoneal fibrosis: preliminary observations. Adv Perit Dial 1995; 11:48-50.
15. Katsumata H, Suzuki H, Ohishi A, Nakamoto H, Saruta T, Sakaguchi H. Effects of antihypertensive agents on blood pressure and the progress of renal failure in partially nephrectomized spontaneously hypertensive rats. Lab Invest 1990; 62:474-80.
16. Nakamoto H, Suzuki H, Ohishi A, Katsumata H, Sakaguchi H, Saruta T. Effects of cicletanine on the progression of renal failure in 5/6 nephrectomized hypertensive rats. Clin Exp Pharmacol Physiol 1999; 26:236-41.
17. Harris PJ, Navar LG. Tubular transport responses to angiotensin. Am J Physiol 1985; 248:F621-30.
18. Jörres A, Gahl GM, Topley N, Neubauer A, Ludat K, Müller C, et al. In-vitro biocompatibility of alternative CAPD fluids; comparison of bicarbonate-buffered and glucose-polymer-based solutions. Nephrol Dial Transplant 1994; 9:785-90.
19. Rooney OB, Dodd PD, Gokal R, Walker MG. Dialysis fluid cytotoxicity and inhibition of host defence in cultured human mesothelial cells are neutralized rapidly with incubation in the peritoneum. Nephrol Dial Transplant 1996; 11:2472-7.
20. Rippe B, Simonsen O, Heimbürger O, Christensson A, Haraldsson B, Stelin G, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59:348-57.
21. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004; 43:1056-64.